tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksFDA CalendarMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement

TipRanks Clinical-Trials-Auto-Generated Newsdesk

TipRanks Reporter

TipRanks’s Recent Articles

Eli Lilly’s New Study on Brenipatide: A Potential Game-Changer in Smoking Cessation
Eli Lilly’s New Study on Brenipatide: A Potential Game-Changer in Smoking Cessation
Eli Lilly And Company (($LLY)) announced an update on their ongoing clinical study. Study Overview: Eli Lilly and...
5d ago
LLY
AstraZeneca’s AZD6234 Study: Key Insights for Investors
AstraZeneca’s AZD6234 Study: Key Insights for Investors
AstraZeneca (($AZN)) announced an update on their ongoing clinical study. AstraZeneca’s recent study titled ‘A Phase I, Multicentre,...
5d ago
AZN
Regeneron’s Aflibercept Study Completion: Implications for Investors
Regeneron’s Aflibercept Study Completion: Implications for Investors
Regeneron Pharmaceuticals (($REGN)) announced an update on their ongoing clinical study. Regeneron Pharmaceuticals, in collaboration with Bayer, has...
5d ago
REGN
Alnylam Pharmaceuticals Launches Promising Phase 3 Study on Nucresiran for hATTR-PN
Alnylam Pharmaceuticals Launches Promising Phase 3 Study on Nucresiran for hATTR-PN
Alnylam Pharmaceuticals (($ALNY)) announced an update on their ongoing clinical study. Alnylam Pharmaceuticals has announced a new clinical...
8d ago
ALNY
Biomea Fusion’s BMF-650: A New Hope in Obesity Treatment?
Biomea Fusion’s BMF-650: A New Hope in Obesity Treatment?
Biomea Fusion Inc (($BMEA)) announced an update on their ongoing clinical study. Biomea Fusion Inc. is conducting a...
8d ago
BMEA
AstraZeneca’s Diabetes Study: Promising Results for FDC Regimen
AstraZeneca’s Diabetes Study: Promising Results for FDC Regimen
AstraZeneca (($AZN)) announced an update on their ongoing clinical study. Study Overview: AstraZeneca’s recent clinical study, officially titled...
8d ago
AZN
AstraZeneca’s New Study on Chronic Kidney Disease: Potential Market Impact
AstraZeneca’s New Study on Chronic Kidney Disease: Potential Market Impact
AstraZeneca (($AZN)) announced an update on their ongoing clinical study. Study Overview: AstraZeneca is conducting a Phase IIb...
9d ago
AZN
AbbVie’s New Phase 1 Study: A Potential Game Changer?
AbbVie’s New Phase 1 Study: A Potential Game Changer?
Abbvie (($ABBV)) announced an update on their ongoing clinical study. AbbVie is currently conducting a Phase 1 clinical...
9d ago
ABBV
Regeneron’s New Study Targets Improved Outcomes in Multiple Myeloma
Regeneron’s New Study Targets Improved Outcomes in Multiple Myeloma
Regeneron Pharmaceuticals (($REGN)) announced an update on their ongoing clinical study. Regeneron Pharmaceuticals is spearheading a pivotal Phase...
9d ago
REGN
AbbVie’s ABBV-1088 Study Termination: Implications for Investors
AbbVie’s ABBV-1088 Study Termination: Implications for Investors
Abbvie (($ABBV)) announced an update on their ongoing clinical study. AbbVie recently updated its clinical study titled ‘A...
9d ago
ABBV
BeOne Medicines’ New Study on BG-75202: A Potential Game-Changer in Cancer Treatment?
BeOne Medicines’ New Study on BG-75202: A Potential Game-Changer in Cancer Treatment?
BeOne Medicines (($ONC)) announced an update on their ongoing clinical study. Study Overview: BeOne Medicines is conducting a...
10d ago
ONC
AstraZeneca’s New Phase I Study on AZD0292: Key Insights for Investors
AstraZeneca’s New Phase I Study on AZD0292: Key Insights for Investors
AstraZeneca (($AZN)) announced an update on their ongoing clinical study. AstraZeneca has initiated a Phase I clinical study...
10d ago
AZN
Eli Lilly’s New Study on Baricitinib: A Potential Game-Changer for Type 1 Diabetes
Eli Lilly’s New Study on Baricitinib: A Potential Game-Changer for Type 1 Diabetes
Eli Lilly And Company (($LLY)) announced an update on their ongoing clinical study. Eli Lilly and Company is...
10d ago
LLY
Eli Lilly’s New Study: Potential Breakthrough in Type 1 Diabetes Prevention
Eli Lilly’s New Study: Potential Breakthrough in Type 1 Diabetes Prevention
Eli Lilly And Company (($LLY)) announced an update on their ongoing clinical study. Study Overview: Eli Lilly and...
10d ago
LLY
Sanofi’s New Study on Balinatunfib: A Potential Game-Changer for IBD Treatment
Sanofi’s New Study on Balinatunfib: A Potential Game-Changer for IBD Treatment
Sanofi (($SNYNF)) announced an update on their ongoing clinical study. Sanofi has initiated a new clinical study titled...
10d ago
SNYNF
AstraZeneca Advances PNH Treatment with Danicopan Study Update
AstraZeneca Advances PNH Treatment with Danicopan Study Update
AstraZeneca (($AZN)) announced an update on their ongoing clinical study. Study Overview: AstraZeneca, in collaboration with Alexion Pharmaceuticals,...
10d ago
AZN
AbbVie’s HIV Treatment Study Update: Key Insights for Investors
AbbVie’s HIV Treatment Study Update: Key Insights for Investors
Abbvie (($ABBV)) announced an update on their ongoing clinical study. AbbVie recently updated its clinical study titled A...
10d ago
ABBV
Neurocrine Biosciences Completes Phase 2 Study on NBI-1070770 for Depression
Neurocrine Biosciences Completes Phase 2 Study on NBI-1070770 for Depression
Neurocrine Biosciences (($NBIX)) announced an update on their ongoing clinical study. Neurocrine Biosciences has recently completed a Phase...
10d ago
NBIX
Regeneron’s Aflibercept Study Sheds Light on Retinal Vasculitis Incidence
Regeneron’s Aflibercept Study Sheds Light on Retinal Vasculitis Incidence
Regeneron Pharmaceuticals (($REGN)) announced an update on their ongoing clinical study. Study Overview: Regeneron Pharmaceuticals recently completed a...
10d ago
REGN
Vanda Pharmaceuticals Advances with Promising Social Anxiety Disorder Treatment Study
Vanda Pharmaceuticals Advances with Promising Social Anxiety Disorder Treatment Study
Vanda Pharmaceuticals (($VNDA)) announced an update on their ongoing clinical study. Study Overview: Vanda Pharmaceuticals is conducting a...
11d ago
VNDA
AstraZeneca’s AZD2693: A Promising Step in NASH Treatment
AstraZeneca’s AZD2693: A Promising Step in NASH Treatment
AstraZeneca (($AZN)) announced an update on their ongoing clinical study. Study Overview: AstraZeneca’s recent clinical study, titled A...
11d ago
AZN
AstraZeneca’s Dapagliflozin Study: Real-World Insights on CKD Treatment
AstraZeneca’s Dapagliflozin Study: Real-World Insights on CKD Treatment
AstraZeneca (($AZN)) announced an update on their ongoing clinical study. Study Overview: The OPTIMISE-CKD CEE study, officially titled...
11d ago
AZN
GSK’s LUNELORD Study: New Insights into Lupus Nephritis
GSK’s LUNELORD Study: New Insights into Lupus Nephritis
GlaxoSmithKline (($GSK)) announced an update on their ongoing clinical study. Study Overview: The LUNELORD study, officially titled A...
11d ago
GSK
Akeso, Inc. Advances Cancer Treatment with New Phase I Study on AK137
Akeso, Inc. Advances Cancer Treatment with New Phase I Study on AK137
Akeso, Inc. (($HK:9926)) announced an update on their ongoing clinical study. Akeso, Inc. is conducting a Phase I...
11d ago
9926
Mind Medicine’s Phase 3 Trial of MM120: A Potential Breakthrough for Depression Treatment
Mind Medicine’s Phase 3 Trial of MM120: A Potential Breakthrough for Depression Treatment
Mind Medicine Inc. (($MNMD)) announced an update on their ongoing clinical study. Study Overview: Mind Medicine Inc. is...
11d ago
MNMD
GSK’s New Phase 3 Study on Efimosfermin Alfa: A Potential Breakthrough for MASH Treatment
GSK’s New Phase 3 Study on Efimosfermin Alfa: A Potential Breakthrough for MASH Treatment
GlaxoSmithKline (($GSK)) announced an update on their ongoing clinical study. GlaxoSmithKline (GSK) is embarking on a pivotal clinical...
11d ago
GSK
ADC Therapeutics’ LOTIS-7 Study: A Promising Update for Investors
ADC Therapeutics’ LOTIS-7 Study: A Promising Update for Investors
ADC Therapeutics Ltd (($ADCT)) announced an update on their ongoing clinical study. ADC Therapeutics Ltd is conducting a...
11d ago
ADCT
Bayer’s New Study on Mirena: A Potential Game-Changer for Endometrial Hyperplasia Treatment
Bayer’s New Study on Mirena: A Potential Game-Changer for Endometrial Hyperplasia Treatment
Bayer AG (($BAYRY)) announced an update on their ongoing clinical study. Bayer AG is launching a new clinical...
11d ago
BAYRY
BioNTech’s Latest Study on BNT327: A Potential Game-Changer in Lung Cancer Treatment
BioNTech’s Latest Study on BNT327: A Potential Game-Changer in Lung Cancer Treatment
Biontech Se Sponsored Adr (($BNTX)) announced an update on their ongoing clinical study. BioNTech SE is currently sponsoring...
11d ago
BNTX
Amgen’s Promising Phase 3 Study on Blinatumomab for Leukemia: What Investors Need to Know
Amgen’s Promising Phase 3 Study on Blinatumomab for Leukemia: What Investors Need to Know
Amgen Inc (($AMGN)) announced an update on their ongoing clinical study. Amgen Inc. is currently conducting a Phase...
11d ago
AMGN
Amgen’s Avacopan Study: A Closer Look at Long-term Safety in ANCA-associated Vasculitis
Amgen’s Avacopan Study: A Closer Look at Long-term Safety in ANCA-associated Vasculitis
Amgen Inc (($AMGN)) announced an update on their ongoing clinical study. Amgen Inc. is conducting a Phase 4...
11d ago
AMGN
Day One Biopharmaceuticals’ Phase 3 Trial: A Potential Game Changer in Pediatric Glioma Treatment
Day One Biopharmaceuticals’ Phase 3 Trial: A Potential Game Changer in Pediatric Glioma Treatment
Day One Biopharmaceuticals, Inc. (($DAWN)) announced an update on their ongoing clinical study. Day One Biopharmaceuticals, Inc. is...
11d ago
DAWN
Genmab and BioNTech’s Promising Study on Metastatic Colorectal Cancer Treatment
Genmab and BioNTech’s Promising Study on Metastatic Colorectal Cancer Treatment
Genmab (Otc) (($GMAB)), Biontech Se Sponsored Adr (($BNTX)) announced an update on their ongoing clinical study. Genmab and...
11d ago
BNTX
GMAB
Ars Pharmaceuticals’ Latest Study: A Potential Game-Changer in Allergy Treatment
Ars Pharmaceuticals’ Latest Study: A Potential Game-Changer in Allergy Treatment
Ars Pharmaceuticals, Inc. (($SPRY)) announced an update on their ongoing clinical study. Study Overview: Ars Pharmaceuticals, Inc. is...
11d ago
SPRY
GSK’s New Phase 3 Study on Efimosfermin Alfa: A Potential Game-Changer for Liver Disease Treatment
GSK’s New Phase 3 Study on Efimosfermin Alfa: A Potential Game-Changer for Liver Disease Treatment
GlaxoSmithKline (($GSK)) announced an update on their ongoing clinical study. GlaxoSmithKline (GSK) has announced a new clinical study...
11d ago
GSK
Daiichi Sankyo’s Latest Clinical Trial: A Potential Game-Changer for Prostate Cancer Treatment
Daiichi Sankyo’s Latest Clinical Trial: A Potential Game-Changer for Prostate Cancer Treatment
Daiichi Sankyo Company (($DSKYF)) announced an update on their ongoing clinical study. Study Overview: The clinical study titled...
11d ago
DSKYF
Daiichi Sankyo’s Promising Pediatric Cancer Study: A Potential Game-Changer
Daiichi Sankyo’s Promising Pediatric Cancer Study: A Potential Game-Changer
Daiichi Sankyo Company (($DSKYF)) announced an update on their ongoing clinical study. Study Overview: The LIGHTBEAM-U01 Substudy 01C,...
11d ago
DSKYF
AstraZeneca’s New Study on NF1 in Egypt: What Investors Need to Know
AstraZeneca’s New Study on NF1 in Egypt: What Investors Need to Know
AstraZeneca (($AZN)) announced an update on their ongoing clinical study. In a recent update, AstraZeneca announced a new...
11d ago
AZN
Incyte’s Ruxolitinib Cream Study: A Potential Game-Changer for Hidradenitis Suppurativa
Incyte’s Ruxolitinib Cream Study: A Potential Game-Changer for Hidradenitis Suppurativa
Incyte (($INCY)) announced an update on their ongoing clinical study. Incyte Corporation is conducting a Phase 3 clinical...
11d ago
INCY
Daiichi Sankyo’s Promising Gastrointestinal Cancer Study: A Market Game-Changer?
Daiichi Sankyo’s Promising Gastrointestinal Cancer Study: A Market Game-Changer?
Daiichi Sankyo Company (($DSKYF)) announced an update on their ongoing clinical study. Study Overview: The clinical study titled...
11d ago
DSKYF
Incyte’s Ruxolitinib Cream Study: A Potential Breakthrough for Pediatric Vitiligo
Incyte’s Ruxolitinib Cream Study: A Potential Breakthrough for Pediatric Vitiligo
Incyte (($INCY)) announced an update on their ongoing clinical study. Study Overview: Incyte Corporation is conducting a Phase...
11d ago
INCY
Daiichi Sankyo’s Latest Clinical Study: A Potential Game-Changer in Gastrointestinal Cancer Treatment
Daiichi Sankyo’s Latest Clinical Study: A Potential Game-Changer in Gastrointestinal Cancer Treatment
Daiichi Sankyo Company (($DSKYF)) announced an update on their ongoing clinical study. Study Overview: The clinical study titled...
11d ago
DSKYF
Edesa Biotech and InflaRx: Breathing New Life into ARDS Treatment
Edesa Biotech and InflaRx: Breathing New Life into ARDS Treatment
Edesa Biotech (($EDSA)), Inflarx N.V. (($IFRX)) announced an update on their ongoing clinical study. Study Overview: The JUST...
11d ago
EDSA
IFRX
Daiichi Sankyo’s Promising Breast Cancer Study: A Financial Perspective
Daiichi Sankyo’s Promising Breast Cancer Study: A Financial Perspective
Daiichi Sankyo Company (($DSKYF)) announced an update on their ongoing clinical study. Study Overview: The clinical study titled...
11d ago
DSKYF
Edesa Biotech and InflaRx: Advancing ARDS Treatment with Bevacizumab
Edesa Biotech and InflaRx: Advancing ARDS Treatment with Bevacizumab
Edesa Biotech (($EDSA)), Inflarx N.V. (($IFRX)) announced an update on their ongoing clinical study. Study Overview: The clinical...
11d ago
EDSA
IFRX
Agios Pharmaceuticals Advances Sickle Cell Treatment with Tebapivat Study
Agios Pharmaceuticals Advances Sickle Cell Treatment with Tebapivat Study
Agios Pharmaceuticals (($AGIO)) announced an update on their ongoing clinical study. Agios Pharmaceuticals is conducting a Phase 2...
11d ago
AGIO
Agios Pharmaceuticals’ AG-236 Study: A Potential Game-Changer in Drug Development
Agios Pharmaceuticals’ AG-236 Study: A Potential Game-Changer in Drug Development
Agios Pharmaceuticals (($AGIO)) announced an update on their ongoing clinical study. Agios Pharmaceuticals has initiated a Phase 1...
11d ago
AGIO
Edesa Biotech and InflaRx: Advancing ARDS Treatment with Vilobelimab
Edesa Biotech and InflaRx: Advancing ARDS Treatment with Vilobelimab
Edesa Biotech (($EDSA)), Inflarx N.V. (($IFRX)) announced an update on their ongoing clinical study. Study Overview: The JUST...
11d ago
EDSA
IFRX
Incyte’s Latest Clinical Study: A Step Forward in Drug Development
Incyte’s Latest Clinical Study: A Step Forward in Drug Development
Incyte (($INCY)) announced an update on their ongoing clinical study. Incyte Corporation is currently conducting a clinical study...
11d ago
INCY
Daiichi Sankyo’s Promising Phase 2 Breast Cancer Study: A Potential Game-Changer
Daiichi Sankyo’s Promising Phase 2 Breast Cancer Study: A Potential Game-Changer
Daiichi Sankyo Company (($DSKYF)) announced an update on their ongoing clinical study. Study Overview: The study titled An...
11d ago
DSKYF